Cargando…

NF-κB as potential target in the treatment of melanoma

The RAS/MAP kinase pathway has attracted attention because activating mutations of the BRAF serine/threonine kinase was described in over 50% of melanomas. Very recently, selective and potent BRAF inhibitors have been developed. Several other signal transduction pathways have been found to be consti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Madonna, Gabriele, Ullman, Claudio Dansky, Gentilcore, Giusy, Palmieri, Giuseppe, Ascierto, Paolo Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338086/ https://www.ncbi.nlm.nih.gov/pubmed/22433222 http://dx.doi.org/10.1186/1479-5876-10-53

Ejemplares similares

Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations
por: Gentilcore, Giusy, et al.
Publicado: (2013)

Main roads to melanoma
por: Palmieri, Giuseppe, et al.
Publicado: (2009)

Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells
por: Fratangelo, Federica, et al.
Publicado: (2018)

Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-α 2b treatment
por: Ascierto, Paolo A, et al.
Publicado: (2010)

Increased HOX C13 expression in metastatic melanoma progression
por: Cantile, Monica, et al.
Publicado: (2012)

Editorial: Advancements in Molecular Diagnosis and Treatment of Melanoma
por: Palmieri, Giuseppe, et al.
Publicado: (2021)

Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma
por: Stucci, Stefania, et al.
Publicado: (2015)

What is changing in the adjuvant treatment of melanoma?
por: Ascierto, Paolo A., et al.
Publicado: (2017)

NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug
por: Caporali, Simona, et al.
Publicado: (2012)

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
por: Capone, Mariaelena, et al.
Publicado: (2018)

Melanoma: From Research to Treatment
por: Ascierto, Paolo A., et al.
Publicado: (2011)

Desmoplastic melanoma: C>Ts and NF‐κB
por: Rabbie, Roy, et al.
Publicado: (2016)

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
por: Morello, Silvana, et al.
Publicado: (2017)

Inhibition of HIV-1 replication in primary human monocytes by the IκB-αS32/36A repressor of NF-κB
por: Palmieri, Camillo, et al.
Publicado: (2004)

NF-κB inhibition is associated with OPN/MMP-9 downregulation in cutaneous melanoma
por: Guarneri, Claudio, et al.
Publicado: (2017)

ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin
por: Ruggiero, Ciro Francesco, et al.
Publicado: (2019)

The Ratio of GrzB(+) − FoxP3(+) over CD3(+) T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma
por: Scognamiglio, Giosuè, et al.
Publicado: (2021)

NF-κB Inhibition Suppresses Experimental Melanoma Lung Metastasis
por: Stansel, Tomoko, et al.
Publicado: (2020)

Charting the NF-κB Pathway Interactome Map
por: Tieri, Paolo, et al.
Publicado: (2012)

Human immunodeficiency virus-1 Tat activates NF-κB via physical interaction with IκB-α and p65
por: Fiume, Giuseppe, et al.
Publicado: (2012)

Phytochemicals targeting NF-κB signaling: Potential anti-cancer interventions
por: Chauhan, Akansha, et al.
Publicado: (2022)

Potential clinical implications of CD4(+)CD26(high) T cells for nivolumab treated melanoma patients
por: Galati, Domenico, et al.
Publicado: (2023)

Immunoscore: a new possible approach for melanoma classification
por: Capone, Mariaelena, et al.
Publicado: (2014)

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
por: Caputo, Emilia, et al.
Publicado: (2014)

Correction: A Novel NF-κB-inducing Kinase-MAPK Signaling Pathway Up-regulates NF-κB Activity in Melanoma Cells
por: Dhawan, Punita, et al.
Publicado: (2022)

Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients
por: Tallerico, Rossana, et al.
Publicado: (2015)

Editorial: Combination Strategies in the Treatment of Melanoma
por: Ascierto, Paolo Antonio
Publicado: (2016)

Co-Targeting Nucleus Accumbens Associate 1 and NF-κB Signaling Synergistically Inhibits Melanoma Growth
por: Gu, Lixiang, et al.
Publicado: (2023)

Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy
por: Mozzillo, Nicola, et al.
Publicado: (2015)

Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors
por: Cristiani, Costanza Maria, et al.
Publicado: (2022)

Targeting NF-κB Signaling for Multiple Myeloma
por: Wong, Ada Hang-Heng, et al.
Publicado: (2020)

New paradigm for stage III melanoma: from surgery to adjuvant treatment
por: Ascierto, Paolo Antonio, et al.
Publicado: (2019)

Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned
por: Trojaniello, Claudia, et al.
Publicado: (2023)

NF-κB potentiates tumor growth by suppressing a novel target LPTS
por: Liu, Dongbo, et al.
Publicado: (2017)

Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma
por: Harder, Nathalie, et al.
Publicado: (2019)

Chemoresistance in H-Ferritin Silenced Cells: The Role of NF-κB
por: Aversa, Ilenia, et al.
Publicado: (2018)

MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab
por: Bifulco, Carlo, et al.
Publicado: (2014)

Eukaryotic Initiation Factor 4H Is under Transcriptional Control of p65/NF-κB
por: Fiume, Giuseppe, et al.
Publicado: (2013)

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
por: Caputo, Emilia, et al.
Publicado: (2015)

MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAF(V600E) Mutation Detected in Circulating-Free DNA
por: Salemi, Rossella, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_32lldhroodtks8jg61p3u3lqdl